Published in J Am Diet Assoc on December 01, 2003
Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. Am J Physiol Gastrointest Liver Physiol (2009) 1.91
Sweet taste receptor expressed in pancreatic beta-cells activates the calcium and cyclic AMP signaling systems and stimulates insulin secretion. PLoS One (2009) 1.71
Artificial sweeteners: a systematic review of metabolic effects in youth. Int J Pediatr Obes (2010) 1.41
Review of the nutritional benefits and risks related to intense sweeteners. Arch Public Health (2015) 1.40
Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2012) 1.35
Artificial sweetener use among children: epidemiology, recommendations, metabolic outcomes, and future directions. Pediatr Clin North Am (2011) 1.09
Sucralose, a synthetic organochlorine sweetener: overview of biological issues. J Toxicol Environ Health B Crit Rev (2013) 1.06
Mechanisms for sweetness. J Nutr (2012) 0.99
The functional role of the T1R family of receptors in sweet taste and feeding. Physiol Behav (2011) 0.94
Male rats show an indifference-avoidance response for increasing concentrations of the artificial sweetener sucralose. Nutr Res (2005) 0.92
Metabolic effects of non-nutritive sweeteners. Physiol Behav (2015) 0.92
Rationale for further medical and health research on high-potency sweeteners. Chem Senses (2012) 0.91
T1R and T2R receptors: the modulation of incretin hormones and potential targets for the treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs (2010) 0.89
Sucralose enhances GLP-1 release and lowers blood glucose in the presence of carbohydrate in healthy subjects but not in patients with type 2 diabetes. Eur J Clin Nutr (2014) 0.87
Effect of the artificial sweetener, acesulfame potassium, a sweet taste receptor agonist, on glucose uptake in small intestinal cell lines. J Gastrointest Surg (2012) 0.85
Sugar substitutes: Health controversy over perceived benefits. J Pharmacol Pharmacother (2011) 0.81
Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research. Rev Endocr Metab Disord (2016) 0.80
Effects of the Non-Nutritive Sweeteners on Glucose Metabolism and Appetite Regulating Hormones: Systematic Review of Observational Prospective Studies and Clinical Trials. PLoS One (2016) 0.78
Lack of functionally active sweet taste receptors in the jejunum in vivo in the rat. J Surg Res (2013) 0.77
Dessert formulation using sucralose and dextrin affects favorably postprandial response to glucose, insulin, and C-peptide in type 2 diabetic patients. Rev Diabet Stud (2013) 0.75
Sucralose Non-Carcinogenicity: A Review of the Scientific and Regulatory Rationale. Nutr Cancer (2016) 0.75
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Hypoglycemia in diabetes. Diabetes Care (2003) 6.19
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol (2013) 5.24
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA (2003) 3.36
Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30
A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med (2009) 3.27
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol (2006) 3.11
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol (2004) 3.02
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med (2003) 2.94
Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. Diabetes Care (2004) 2.92
Comparisons of waist circumferences measured at 4 sites. Am J Clin Nutr (2003) 2.78
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Measurement of human daily physical activity. Obes Res (2003) 2.62
Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr (2008) 2.55
Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. Circulation (2009) 2.49
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) (2010) 2.25
Improving energy expenditure estimation for physical activity. Med Sci Sports Exerc (2004) 2.20
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2007) 2.14
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care (2012) 2.08
Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care (2013) 2.03
Anxiety and poor glycemic control: a meta-analytic review of the literature. Int J Psychiatry Med (2002) 2.02
Is percentage body fat differentially related to body mass index in Hispanic Americans, African Americans, and European Americans? Am J Clin Nutr (2003) 2.01
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther (2008) 1.95
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
Obesity-related leptin regulates Alzheimer's Abeta. FASEB J (2004) 1.85
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 1.85
Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care (2003) 1.85
Adipose tissue distribution is different in type 2 diabetes. Am J Clin Nutr (2009) 1.78
Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci (2012) 1.76
Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther (2003) 1.74
The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol (2005) 1.66
Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol (2007) 1.65
Adiponectin in health and disease. Diabetes Obes Metab (2007) 1.64
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril (2007) 1.63
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes (2003) 1.62
Body weight changes with beta-blocker use: results from GEMINI. Am J Med (2007) 1.60
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension (2005) 1.54
Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus. J Clin Endocrinol Metab (2011) 1.52
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51
Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep (2013) 1.50
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab (2007) 1.49
Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes (2010) 1.46
Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry (2006) 1.45
Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes (2007) 1.45
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol (2007) 1.45
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg (2008) 1.45
Evaluation of early weight loss thresholds for identifying nonresponders to an intensive lifestyle intervention. Obesity (Silver Spring) (2014) 1.44
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 1.44
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
Validation of a 3-dimensional photonic scanner for the measurement of body volumes, dimensions, and percentage body fat. Am J Clin Nutr (2006) 1.40
Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care (2010) 1.40
The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care (2005) 1.36
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care (2002) 1.35
Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol (2006) 1.35
Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab (2003) 1.33
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest (2011) 1.33
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
A multilevel ecological approach to promoting walking in rural communities. Prev Med (2005) 1.30
Physical disability and obesity. Nutr Rev (2005) 1.28
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract (2003) 1.26
The body adiposity index (hip circumference ÷ height(1.5)) is not a more accurate measure of adiposity than is BMI, waist circumference, or hip circumference. Obesity (Silver Spring) (2012) 1.26
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J (2005) 1.25
Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control. J Am Coll Cardiol (2005) 1.25
Intentional weight loss reduces mortality rate in a rodent model of dietary obesity. Obes Res (2005) 1.24
Activity patterns of obese adults with type 2 diabetes in the look AHEAD study. Med Sci Sports Exerc (2010) 1.24
Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes (2009) 1.23
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care (2012) 1.22
A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care (2010) 1.21
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther (2013) 1.17
Body mass index and all-cause mortality in a large Chinese cohort. CMAJ (2011) 1.15
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes (2002) 1.15
Depression and coronary heart disease in women with diabetes. Psychosom Med (2003) 1.15
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int (2002) 1.15
Metabolic inflexibility in substrate use is present in African-American but not Caucasian healthy, premenopausal, nondiabetic women. J Clin Endocrinol Metab (2006) 1.14
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes. Diabetes (2002) 1.13
Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care (2007) 1.12
Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int (2003) 1.11
Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol (2003) 1.11